公开(公告)号：WO2011025230A9

公开(公告)日：2011-03-03

申请号：PCT/KR2010/005653

申请日：2010-08-24

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  LEE, Changjoon Justin ,  LEE, Soo-Jung ,  YOON, Bo-Eun

Inventor： LEE, Changjoon Justin ,  LEE, Soo-Jung ,  YOON, Bo-Eun

IPC: A61K31/465 ,  A61K31/7105 ,  A61P25/08 ,  A61P25/28

Abstract: A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1(Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided.

公开(公告)号：EP2470180B1

公开(公告)日：2014-03-12

申请号：EP10812243.3

申请日：2010-08-24

Applicant: Korea Institute of Science and Technology

Inventor： LEE, Changjoon Justin ,  LEE, Soo-Jung ,  YOON, Bo-Eun

IPC: A61K31/465 ,  A61K31/7105 ,  G01N33/48 ,  A61P25/08 ,  A61P25/28 ,  A61P25/00

CPC classification number: A61K31/00 ,  A61K31/185 ,  A61K31/196 ,  A61K31/455 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/043 ,  A61K38/08 ,  G01N33/9426 ,  G01N2500/10

公开(公告)号：EP2470180A2

公开(公告)日：2012-07-04

申请号：EP10812243.3

申请日：2010-08-24

Applicant: Korea Institute of Science and Technology

Inventor： LEE, Changjoon Justin ,  LEE, Soo-Jung ,  YOON, Bo-Eun

IPC: A61K31/465 ,  A61K31/7105 ,  A61P25/08 ,  A61P25/28

CPC classification number: A61K31/00 ,  A61K31/185 ,  A61K31/196 ,  A61K31/455 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/043 ,  A61K38/08 ,  G01N33/9426 ,  G01N2500/10

Abstract: A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1(Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided.